AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$GMAB

GENMAB A/S

Price · $GMABvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $GMAB in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $GMAB in the last 30 days.

Top stories · $GMABMore →
MAY 18·AD HOC NEWSHigh

Genmab A/S stock (DK0010272202): antibody specialist in focus after latest earnings and pipeline upd

Genmab A/S, a Danish antibody specialist, is gaining investor attention following its latest quarterly earnings and pipeline updates. The company's business model relies on antibody-based therapies, particularly in oncology, driven by partnerships with major pharmaceutical groups and a growing internal pipeline. Key revenue sources include royalties from drugs like Darzalex and its own commercialized product, Tivdak, while it faces risks from clinical development, revenue concentration, and regulatory changes in a competitive biotechnology landscape.

MAY 12·Oncodaily

Jan van de Winkel: Harnessing the Power of Antibodies to Transform Patients’ Lives

Jan van de Winkel, CEO of Genmab, discusses the company's commitment to transforming patients' lives through antibody science. He emphasizes Genmab's evolving approach, taking greater ownership from discovery to patient care, all while maintaining its core purpose of patient-centric science to expand its impact in medicine.

APR 17·TipRanks

Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility

Genmab (GMAB) has updated its Articles of Association, formalizing authorizations for the board to issue new shares, employee warrants, and convertible debt. These changes provide the company with increased flexibility for capital raising and employee incentive structures, potentially supporting future financing and expansion efforts without frequent shareholder meetings. While the company demonstrates strong financial performance and a constructive earnings outlook, TipRanks’ AI Analyst, Spark, rates GMAB as Neutral, citing concerns over a sharp 2025 leverage increase and weaker earnings quality signals.

News on $GMAB

All news →